Notícias Contineum Therapeutics Inc - CTNM | Ações NASDAQ | ADVFN Brasil

Índice Bovespa

US Dollar vs BRL

As Melhores Corretoras Online

Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Contineum Therapeutics Inc (CTNM)
Contineum Therapeutics Inc (CTNM) Notícias

Contineum Therapeutics Inc (CTNM)

12,965

-0,325

( -2,45% )

Atualizado: 14:22:26

Atrasado por 15 minutos

Ferramentas de nível profissional para investidores individuais.

Contineum Therapeutics Completes Enrollment in Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)

RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s Board of Directors

Contineum Therapeutics Initiates Patient Dosing in Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791

Form 4 - Statement of changes in beneficial ownership of securities

Contineum Therapeutics to Attend the 7th Annual Evercore HealthCONx Conference

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain

Contineum Therapeutics to Attend Upcoming Investor Conferences

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Contineum Therapeutics to Present at Multiple Upcoming Investor Conferences

Form 4 - Statement of changes in beneficial ownership of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Fóruns

Nenhuma Discussão Encontrada

Criar Nova Discussão

Contineum Therapeutics

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições